Search

Your search keyword '"Saliby, Renee Maria"' showing total 3 results
Start Over Author "Saliby, Renee Maria" Database OAIster
3 results on '"Saliby, Renee Maria"'

1. Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.

Author

Johnson, Douglas B, Johnson, Douglas B, Atkins, Michael B, Hennessy, Cassandra, Wise-Draper, Trisha, Heilman, Hannah, Awosika, Joy, Bakouny, Ziad, Labaki, Chris, Saliby, Renee Maria, Hwang, Clara, Singh, Sunny RK, Balanchivadze, Nino, Friese, Christopher R, Fecher, Leslie A, Yoon, James J, Hayes-Lattin, Brandon, Bilen, Mehmet A, Castellano, Cecilia A, Lyman, Gary H, Tachiki, Lisa, Shah, Sumit A, Glover, Michael J, Flora, Daniel B, Wulff-Burchfield, Elizabeth, Kasi, Anup, Abbasi, Saqib H, Farmakiotis, Dimitrios, Viera, Kendra, Klein, Elizabeth J, Weissman, Lisa B, Jani, Chinmay, Puc, Matthew, Fahey, Catherine C, Reuben, Daniel Y, Mishra, Sanjay, Beeghly-Fadiel, Alicia, French, Benjamin, Warner, Jeremy L, COVID-19 and Cancer Consortium, Johnson, Douglas B, Johnson, Douglas B, Atkins, Michael B, Hennessy, Cassandra, Wise-Draper, Trisha, Heilman, Hannah, Awosika, Joy, Bakouny, Ziad, Labaki, Chris, Saliby, Renee Maria, Hwang, Clara, Singh, Sunny RK, Balanchivadze, Nino, Friese, Christopher R, Fecher, Leslie A, Yoon, James J, Hayes-Lattin, Brandon, Bilen, Mehmet A, Castellano, Cecilia A, Lyman, Gary H, Tachiki, Lisa, Shah, Sumit A, Glover, Michael J, Flora, Daniel B, Wulff-Burchfield, Elizabeth, Kasi, Anup, Abbasi, Saqib H, Farmakiotis, Dimitrios, Viera, Kendra, Klein, Elizabeth J, Weissman, Lisa B, Jani, Chinmay, Puc, Matthew, Fahey, Catherine C, Reuben, Daniel Y, Mishra, Sanjay, Beeghly-Fadiel, Alicia, French, Benjamin, Warner, Jeremy L, and COVID-19 and Cancer Consortium

Abstract

IntroductionCOVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients with melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated with COVID-19 severity among patients with melanoma, particularly assessing outcomes of patients on active targeted or immune therapy.MethodsUsing the COVID-19 and Cancer Consortium (CCC19) registry, we identified 307 patients with melanoma diagnosed with COVID-19. We used multivariable models to assess demographic, cancer-related, and treatment-related factors associated with COVID-19 severity on a 6-level ordinal severity scale. We assessed whether treatment was associated with increased cardiac or pulmonary dysfunction among hospitalized patients and assessed mortality among patients with a history of melanoma compared with other cancer survivors.ResultsOf 307 patients, 52 received immunotherapy (17%), and 32 targeted therapy (10%) in the previous 3 months. Using multivariable analyses, these treatments were not associated with COVID-19 severity (immunotherapy OR 0.51, 95% CI 0.19 - 1.39; targeted therapy OR 1.89, 95% CI 0.64 - 5.55). Among hospitalized patients, no signals of increased cardiac or pulmonary organ dysfunction, as measured by troponin, brain natriuretic peptide, and oxygenation were noted. Patients with a history of melanoma had similar 90-day mortality compared with other cancer survivors (OR 1.21, 95% CI 0.62 - 2.35).ConclusionsMelanoma therapies did not appear to be associated with increased severity of COVID-19 or worsening organ dysfunction. Patients with history of melanoma had similar 90-day survival following COVID-19 compared with other cancer survivors.

Published
2023

2. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19

Author

Gulati, Shuchi, Hsu, Chih-Yuan, Shah, Surbhi, Shah, Pankil K., Zon, Rebecca, Alsamarai, Susan, Awosika, Joy, El-Bakouny, Ziad, Bashir, Babar, Beeghly, Alicia, Berg, Stephanie, de-la-Rosa-Martinez, Daniel, Doroshow, Deborah B., Egan, Pamela C., Fein, Joshua, Flora, Daniel B., Friese, Christopher R., Fromowitz, Ariel, Griffiths, Elizabeth A., Hwang, Clara, Jani, Chinmay, Joshi, Monika, Khan, Hina, Klein, Elizabeth J., Heater, Natalie Knox, Koshkin, Vadim S., Kwon, Daniel H., Labaki, Chris, Latif, Tahir, McKay, Rana R., Nagaraj, Gayathri, Nakasone, Elizabeth S., Nonato, Taylor, Polimera, Hyma V., Puc, Matthew, Razavi, Pedram, Ruiz-Garcia, Erika, Saliby, Renee Maria, Shastri, Aditi, Singh, Sunny R.K., Tagalakis, Vicky, Vilar-Compte, Diana, Weissmann, Lisa B., Wilkins, Cy R., Wise-Draper, Trisha M., Wotman, Michael T., Yoon, James J., Mishra, Sanjay, Grivas, Petros, Shyr, Yu, Warner, Jeremy L., Connors, Jean M., Shah, Dimpy P., Rosovsky, Rachel P., Gulati, Shuchi, Hsu, Chih-Yuan, Shah, Surbhi, Shah, Pankil K., Zon, Rebecca, Alsamarai, Susan, Awosika, Joy, El-Bakouny, Ziad, Bashir, Babar, Beeghly, Alicia, Berg, Stephanie, de-la-Rosa-Martinez, Daniel, Doroshow, Deborah B., Egan, Pamela C., Fein, Joshua, Flora, Daniel B., Friese, Christopher R., Fromowitz, Ariel, Griffiths, Elizabeth A., Hwang, Clara, Jani, Chinmay, Joshi, Monika, Khan, Hina, Klein, Elizabeth J., Heater, Natalie Knox, Koshkin, Vadim S., Kwon, Daniel H., Labaki, Chris, Latif, Tahir, McKay, Rana R., Nagaraj, Gayathri, Nakasone, Elizabeth S., Nonato, Taylor, Polimera, Hyma V., Puc, Matthew, Razavi, Pedram, Ruiz-Garcia, Erika, Saliby, Renee Maria, Shastri, Aditi, Singh, Sunny R.K., Tagalakis, Vicky, Vilar-Compte, Diana, Weissmann, Lisa B., Wilkins, Cy R., Wise-Draper, Trisha M., Wotman, Michael T., Yoon, James J., Mishra, Sanjay, Grivas, Petros, Shyr, Yu, Warner, Jeremy L., Connors, Jean M., Shah, Dimpy P., and Rosovsky, Rachel P.

Abstract

IMPORTANCE: Systematic data on the association between anticancer therapies and thromboembolic events (TEEs) in patients with COVID-19 are lacking. OBJECTIVE: To assess the association between anticancer therapy exposure within 3 months prior to COVID-19 and TEEs following COVID-19 diagnosis in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This registry-based retrospective cohort study included patients who were hospitalized and had active cancer and laboratory-confirmed SARS-CoV-2 infection. Data were accrued from March 2020 to December 2021 and analyzed from December 2021 to October 2022. EXPOSURE: Treatments of interest (TOIs) (endocrine therapy, vascular endothelial growth factor inhibitors/tyrosine kinase inhibitors [VEGFis/TKIs], immunomodulators [IMiDs], immune checkpoint inhibitors [ICIs], chemotherapy) vs reference (no systemic therapy) in 3 months prior to COVID-19. MAIN OUTCOMES AND MEASURES: Main outcomes were (1) venous thromboembolism (VTE) and (2) arterial thromboembolism (ATE). Secondary outcome was severity of COVID-19 (rates of intensive care unit admission, mechanical ventilation, 30-day all-cause mortality following TEEs in TOI vs reference group) at 30-day follow-up. RESULTS: Of 4988 hospitalized patients with cancer (median [IQR] age, 69 [59-78] years; 2608 [52%] male), 1869 had received 1 or more TOIs. Incidence of VTE was higher in all TOI groups: endocrine therapy, 7%; VEGFis/TKIs, 10%; IMiDs, 8%; ICIs, 12%; and chemotherapy, 10%, compared with patients not receiving systemic therapies (6%). In multivariable log-binomial regression analyses, relative risk of VTE (adjusted risk ratio [aRR], 1.33; 95% CI, 1.04-1.69) but not ATE (aRR, 0.81; 95% CI, 0.56-1.16) was significantly higher in those exposed to all TOIs pooled together vs those with no exposure. Among individual drugs, ICIs were significantly associated with VTE (aRR, 1.45; 95% CI, 1.01-2.07). Also noted were significant associations between VTE and active and progressing ca

Published
2023

3. Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.

Author

Wagner, Michael J, Wagner, Michael J, Hennessy, Cassandra, Beeghly, Alicia, French, Benjamin, Shah, Dimpy P, Croessmann, Sarah, Vilar-Compte, Diana, Ruiz-Garcia, Erika, Ingham, Matthew, Schwartz, Gary K, Painter, Corrie A, Chugh, Rashmi, Fecher, Leslie, Park, Cathleen, Zamulko, Olga, Trent, Jonathan C, Subbiah, Vivek, Khaki, Ali Raza, Tachiki, Lisa, Nakasone, Elizabeth S, Loggers, Elizabeth T, Labaki, Chris, Saliby, Renee Maria, McKay, Rana R, Ajmera, Archana, Griffiths, Elizabeth A, Puzanov, Igor, Tap, William D, Hwang, Clara, Tejwani, Sheela, Jhawar, Sachin R, Hayes-Lattin, Brandon, Wulff-Burchfield, Elizabeth, Kasi, Anup, Reuben, Daniel Y, Nagaraj, Gayathri, Joshi, Monika, Polimera, Hyma, Kulkarni, Amit A, Esfahani, Khashayar, Kwon, Daniel H, Paoluzzi, Luca, Bilen, Mehmet A, Durbin, Eric B, Grivas, Petros, Warner, Jeremy L, Davis, Elizabeth J, COVID-19 and Cancer Consortium, Wagner, Michael J, Wagner, Michael J, Hennessy, Cassandra, Beeghly, Alicia, French, Benjamin, Shah, Dimpy P, Croessmann, Sarah, Vilar-Compte, Diana, Ruiz-Garcia, Erika, Ingham, Matthew, Schwartz, Gary K, Painter, Corrie A, Chugh, Rashmi, Fecher, Leslie, Park, Cathleen, Zamulko, Olga, Trent, Jonathan C, Subbiah, Vivek, Khaki, Ali Raza, Tachiki, Lisa, Nakasone, Elizabeth S, Loggers, Elizabeth T, Labaki, Chris, Saliby, Renee Maria, McKay, Rana R, Ajmera, Archana, Griffiths, Elizabeth A, Puzanov, Igor, Tap, William D, Hwang, Clara, Tejwani, Sheela, Jhawar, Sachin R, Hayes-Lattin, Brandon, Wulff-Burchfield, Elizabeth, Kasi, Anup, Reuben, Daniel Y, Nagaraj, Gayathri, Joshi, Monika, Polimera, Hyma, Kulkarni, Amit A, Esfahani, Khashayar, Kwon, Daniel H, Paoluzzi, Luca, Bilen, Mehmet A, Durbin, Eric B, Grivas, Petros, Warner, Jeremy L, Davis, Elizabeth J, and COVID-19 and Cancer Consortium

Abstract

BackgroundPatients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.MethodsWe performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed.Resultsof 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity.ConclusionsPatients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results